There are no products listed under this category.
SLC22A18
SLC22A18 (solute carrier family 67 member 1, also known as SLC67A1, TSSC5, BWR1A, IMPT1, ORCTL2 and SLC22A1L) is a membrane transporter of the organic cation transporter family. It may move organic cations by proton efflux antiport and has been linked to lipid metabolism regulation. Browse Assay Genie's current range of SLC22A18 research reagents below, or read on for the biology behind the target.
SLC22A18 may act as a transporter of organic cations through a proton efflux antiport mechanism. It may contribute to the transport of chloroquine and quinidine-related compounds in the kidney, and it plays a role in the regulation of lipid metabolism. The protein is found at the apical cell membrane. It belongs to the major facilitator superfamily (TC 2.A.1) and, within it, to the organic cation transporter family (TC 2.A.1.19).
The SLC22A18 gene is the human member of HGNC's solute carrier family 67 and is now formally named solute carrier family 67 member 1 (SLC67A1). Mouse and rat both carry a Slc67a1 ortholog. Several alternatively spliced transcript variants encoding different isoforms have been described, so researchers working with an SLC22A18 antibody or an SLC22A18 ELISA kit should consider which isoforms are relevant to their question.
The gene is one of several tumour-suppressing subtransferable fragments in the imprinted domain of 11p15.5, an important tumour-suppressor region, which explains aliases such as TSSC5 and BWR1A. Alterations in this region have been associated with Beckwith-Wiedemann syndrome, Wilms tumour, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian and breast cancer. SLC22A18 is imprinted, with preferential expression from the maternal allele, and mutations have been found in Wilms' tumour and lung cancer. Earlier names included solute carrier family 22 member 18 and organic cation transporter-like 2 (ORCTL2), reflecting its original classification before the move to family 67.
The gene lies in a tumour-suppressor region of 11p15.5, with mutations reported in Wilms' tumour and lung cancer.
SLC22A18 is imprinted and preferentially expressed from the maternal allele, making it relevant to imprinted-domain studies.
The protein may transport chloroquine and quinidine-related compounds in kidney, supporting studies of organic cation handling.
SLC22A18 plays a role in the regulation of lipid metabolism, linking a membrane transporter to metabolic control.
SLC22A18 may act as an organic cation transporter using a proton efflux antiport mechanism. It may help transport chloroquine and quinidine-related compounds in the kidney, and it plays a role in regulating lipid metabolism. It localises to the apical cell membrane.
The gene was named from several angles: BWR1A, BWSCR1A and TSSC5 reflect its position in the 11p15 tumour-suppressor region, while ORCTL2 and SLC22A1L reflect similarity to organic cation transporters. HGNC now names it solute carrier family 67 member 1 (SLC67A1).
Mouse and rat each have a Slc67a1 ortholog. Human SLC22A18 is imprinted, and mutations have been found in Wilms' tumour and lung cancer. Its region is also associated with Beckwith-Wiedemann syndrome. Check the datasheet of any product for its validated reactivity.
Other solute carrier transporters, including organic cation, monocarboxylate and vesicular amine transporters.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q96BI1; product specifications from Assay Genie datasheets.
There are no products listed under this category.